RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for La Jolla Pharmaceutical Company Stock and on which exchange is it traded?
The symbol for La Jolla Pharmaceutical Company is LJPC and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell La Jolla Pharmaceutical Company Stock?
La Jolla Pharmaceutical Company holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy La Jolla Pharmaceutical Company Stock?
La Jolla Pharmaceutical Company Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy La Jolla Pharmaceutical Company Stock.

What's the current price of La Jolla Pharmaceutical Company Stock?
As of the end of day on the 2023-01-27, the price of an La Jolla Pharmaceutical Company (LJPC) share was $6.22.

What is the 52-week high and low for La Jolla Pharmaceutical Company Stock?
The 52-week high for La Jolla Pharmaceutical Company Stock is $6.24 and the 52-week low is $3.07.
Click to get the best stock tips daily for free!

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age ... LJPC Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT